What independent testing proves about a research peptide, why in-house results are not enough, what ISO/IEC 17025 does and does not mean, how to check a lab and a certificate yourself, and what 19 of our own published lots show.
Third-party testing means a laboratory with no stake in the sale analyzes a sample from a specific production lot and signs the result under its own name. For a research peptide it answers three separate questions: is it the right molecule (identity, by mass spectrometry), how much of what the instrument detects is that molecule (purity, by HPLC), and how much of it is actually in the vial (net content). A trustworthy result is tied to a lot number, names the lab, and can be checked with that lab.
An experiment is only as reliable as the materials that go into it. If a peptide is not what its label says, or is present at a different purity or amount, every result built on it inherits that error, and nothing in the data will announce the problem. Independent testing is how a researcher gets evidence about a compound from someone other than the party selling it. This guide explains why that independence matters, what the tests measure, what accreditation does and does not guarantee, how to check a laboratory and a certificate for yourself, and what our own published results look like.
Irreproducibility is an expensive, well-documented problem in life science. An economic analysis of preclinical research estimated that the cumulative prevalence of irreproducible studies exceeds 50%, corresponding to roughly $28 billion a year in the United States alone [1]. The authors grouped the causes into four categories, one of which is biological reagents and reference materials, and identified reagents as one of the two areas where improvement would pay off most [1].
For peptides specifically, a label claim is not evidence of what is in the vial. A 2024 study made test purchases of semaglutide sold without a prescription by illegal online pharmacies and analyzed the vials that arrived. Measured semaglutide purity ranged from 7.7% to 14.37%, against the 99% printed on the product labels; the measured semaglutide content exceeded the labeled amount by 28.56% to 38.69%; and endotoxin was detected in every sample, although no viable microorganisms were found [4]. Each of those vials carried a label; only analysis revealed the gap, and it also showed that purity and quantity are separate questions that can each be wrong in a different direction.
In-house testing is not worthless. Manufacturers need their own analytical labs for process control, and many are competent. The difficulty is structural: when the party that profits from a passing result also produces the result, there is an incentive to choose favorable methods, retest until a sample passes, or report only the good lots, and an outside reader has no way to tell whether any of that happened.
Clinical research offers a measured example of how sponsorship shapes outcomes. A systematic review of 30 studies found that research sponsored by pharmaceutical companies was more likely to report outcomes favoring the sponsor than research with other funding, with an odds ratio of 4.05, even though the industry-funded studies were not found to be of poorer methodological quality [2]. The explanations the authors offered included choice of comparator and publication bias, which are decisions about what to test and what to show rather than errors in the measurements themselves [2]. The same incentive applies to a seller testing its own compounds, which is why independent testing, and publishing the results whatever they are, carries more weight.
Independence also has limits worth understanding. The seller usually pays the outside lab, and the lab tests the sample it receives. Independence is strongest when the lab has no ownership ties to the seller, the report names the lab and can be traced back to it, the sample is linked to a specific production lot, and results are published for lots whether or not they flatter the product.
Pharmacopoeial specifications for peptide drugs are built around three core questions: identification, purity, and assay (how much of the compound is present) [5]. Research-grade peptides have no official monographs, and a comparison of the European and United States pharmacopoeias found their peptide specifications were not well harmonized even for approved drugs [5], so for research materials it is up to the buyer to see which of these questions a given report actually answers.
Purity and net content are the two numbers most often confused. A vial can be 99.5% pure and still hold less peptide than its label says, or more. Our companion guide, How to Read a Peptide Certificate of Analysis, walks through each of these fields on a real certificate.
ISO/IEC 17025 is the international standard for the competence of testing and calibration laboratories. It covers both how the laboratory is managed and how it does technical work, and it requires the lab to operate impartially. An accredited laboratory has been assessed by an independent accreditation body against that standard for a defined list of tests, known as its scope of accreditation.
One laboratory's account of implementing the standard gives a sense of what it involves in practice: formal staff training plans and records, documented method development and validation, estimation of measurement uncertainty, a defined calibration and maintenance program for equipment, document control, corrective and preventive action procedures, internal audits, and regular review of proficiency testing results [3]. Proficiency testing is especially useful to an outside reader, since it means the lab periodically analyzes samples of unknown value and is compared against other labs.
You do not need a laboratory to check a certificate. Six checks, done in a few minutes, catch most fabricated or recycled reports.
A certificate library is easier to judge as a whole than one report at a time. As of November 2026 we have published certificates for 20 lots across 18 products, tested by independent laboratories in August and October 2026. Every one is in the COA library, searchable by lot number.
Every Northbridge Research Labs batch is independently tested by a third-party laboratory. Our lot certificates report identity, HPLC purity and net content, name the testing lab, and carry an accession number the lab can look up. Each new production run has its lot number printed on the vial, and the COA library pulls up the certificate for that lot. Products do not ship with a printed certificate; the online library is the record, and earlier batches are still being added. If you cannot find your lot, contact our support team.
Our Purity Guarantee backs the published numbers: if independent testing does not confirm the stated purity, you get a full refund and a free replacement. We encourage researchers to apply every check above to our certificates exactly as they would to anyone else's. Company details and documentation for reviewers are collected on our verification page.
Note: Northbridge Research Labs supplies compounds for laboratory research use only. They are not for human or veterinary use. Independent testing documents the identity and quality of research materials; it does not make them suitable for any use outside the laboratory.
A section-by-section guide to peptide COAs: mass-spec identity, HPLC purity, net content, lot numbers and the red flags of recycled certificates, walked through on real published Northbridge lots.
What an HPLC purity figure measures and what it leaves out, how net peptide content differs from purity, and which impurities, from deletion sequences to racemized residues and TFA counter-ions, matter for research results.
Research Use Only: The information in this article is for educational and research purposes only. All products mentioned are intended for laboratory research use only and are not approved for human or veterinary use.